Literature DB >> 29627026

Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature.

Adam Baghban1, Maricar Malinis2.   

Abstract

Cytomegalovirus (CMV) is a ubiquitous herpesvirus which establishes lifelong latency following primary infection. It is then capable of reactivating in the face of immunosuppression. Encephalitis is a less common, but particularly devastating syndrome associated with CMV. Here, we describe a case of CMV encephalitis in an allogeneic hematopoietic stem cell transplant recipient who received dual antiviral therapy with ganciclovir and foscarnet. The case presentation is followed by a summary of cases reported in the last ten years, with the goal of describing vulnerable patient populations, treatment courses, and outcomes. Finally, the discussion includes a review of the literature, with a focus on diagnostic criteria and the role for dual antiviral therapy in CMV encephalitis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytomegalovirus; Encephalitis; Foscarnet; Ganciclovir; Immunosuppressed; Stem cell transplant

Mesh:

Substances:

Year:  2018        PMID: 29627026     DOI: 10.1016/j.jns.2018.02.029

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Standard treatment-refractory cytomegalovirus encephalitis unmasked by immune reconstitution inflammatory syndrome and successfully treated with virus-specific hyperimmune globulin.

Authors:  Natalia Maximova; Annalisa Marcuzzi; Irene Del Rizzo; Davide Zanon; Alessandra Maestro; Egidio Barbi; Roberto Sala
Journal:  Clin Transl Immunology       Date:  2020-11-17

2.  Severe cytomegalovirus encephalitis in an immunocompetent healthy young woman: A case report.

Authors:  MohammadHossein Mozafarybazargany; Nahid Abbasi Khoshsirat
Journal:  IDCases       Date:  2022-01-13

3.  Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report.

Authors:  Hung-Chuan Yu; Wang-Da Liu; Po-Hsien Kuo; Chien-Chin Lin; Un-In Wu
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.